Article
The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor.
Drug metabolism and disposition: the biological fate of chemicals - 1 May 2006
Tenmizu Daisuke, Noguchi Kiyoshi, Kamimura Hidetaka, Ohtani Hisakazu, Sawada Yasufumi
Abstract excerpt
In a previous study, it was shown that the novel canine single nucleotide polymorphism (SNP) CYP1A2 1117C>T yields an inactive enzyme. In this study, the effect that this SNP has on the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1H)-one (YM-64227) was investigated. Plasma concentrations of the unchanged drug and five of its metabolites (MM-1 to MM-5) were determined after either...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.